Completed clinical trials with ICIs in TETs
| Reference | Treatment | TM/TC | PD-L1 cut-off | PD-L1 positive cases | Primary endpoint | mOS | mPFS | ORR |
|---|---|---|---|---|---|---|---|---|
| Giaccone et al. [44] | Pembrolizumab | 0/40 | PD-L1high: ≥ 50% | 10/37 (27%) | ORR | Un | 4.2 | - |
| PD-L1low: 1–49% | 27/37 (73%) | 15.5 | 2.9 | |||||
| Cho et al. [43] | Pembrolizumab | 7/26 | PD-L1high: ≥ 50% | 14/24 (58.3%) | ORR | - | - | 35.7% |
| PD-L1low: 1–49% | 10/24 (41.7%) | - | - | NR |
mPFS: median PFS; mOS: median OS; Un: unachieved; NR: no response; -: blank cells